Cell and gene therapy care at home

Deliver better care and margins with cell and gene therapy at home.

Bring care episodes for cell and gene therapies home with confidence, while improving safety, scale, and speed. Leverage our evidence-based models for CAR-T, BiTE, and BMT.

Get started

a cancer patient receiving cell and gene therapy at home

Why home-based cell and gene therapy needs the right infrastructure.

Many health systems have already taken the first step toward outpatient models for cell and gene therapy. But delivering these therapies safely and sustainably in the home requires more than a clinical protocol—it takes the right infrastructure.

That means real-time visibility into patient safety. Clear escalation paths. A way to deploy staff efficiently while reducing their load. And operations that can actually scale.

That’s where we come in. We provide the clinical support, operational systems, and 24/7 responsiveness that help your outpatient model perform—so you can deliver more therapies, to more patients, with greater control.

Leading the way in defining
what good looks like.

Our clinical research has demonstrated:

A graphic showing elements of bringing cell and gene therapy episodes home

75 %

of CAR-T shifted to outpatient model

4 Day

avg. inpatient LOS, compared to 16 days

85 %

wearable adherence

206 mins

earlier detection of CRS than standard of care

Proven safe, scalable, and margin-positive

You don’t have to guess if home-based cell and gene therapy works. It’s already being done—safely, at scale, and with impressive results.

In peer-reviewed research, our algorithm identified signs of cytokine release syndrome (CRS) up to 206 minutes earlier than standard of care approaches . That kind of lead time can be the difference between timely intervention and costly escalation.

Sarah Cannon has transitioned 75%+ of CAR-T patients to outpatient care, with safety supported by our real-time monitoring and smart escalation pathways.

Our infrastructure helps reduce unnecessary admissions, streamline staffing needs, and protect reimbursement—all without compromising clinical quality.

Your clinical operating system for better cell and gene therapy experiences.

Proven pathways to get
patients home sooner.

Don’t start from scratch. Build on our research and lessons learned to launch your model for cell and gene therapy at home sooner.

Continuous vital sign monitoring for high-risk days post-treatment
Tailored protocols for detecting CRS, ICANS, and infections early for easier management
Medication adherence checks, symptom triage, and early escalation alerts
Support services for technology, monitoring, and logistics

Data, insights, and integration that fit your team

Your clinicians get the right data at the right time—without toggling between tools.

Seamless integration with Epic and major EHRs
Dashboards that surface real-time data and symptom flags
Automated alerts with smart routing that minimize burdens to clinicians
ePRO and symptom surveys to create the full picture of each patient

See how leading systems are delivering cell and gene therapy at home.

Sarah Cannon, the cancer institute of HCA Healthcare, moved over 75% of CAR-T therapies to outpatient care using our platform.

With continuous monitoring, 24/7 support, and smart escalation:

1,200+ bed days saved across the first 100 patients
75% of CAR-T patients treated with outpatient model
75% reduction in inpatient stay for remaining patients (4-day median vs. 16 days)